Plain-English translation of NCT06949033 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether cadonilimab, a new medication that helps your immune system fight cancer, works better when combined with standard chemotherapy (called SOX) for advanced stomach or gastroesophageal junction cancer. Half of the participants will receive the new medication plus chemotherapy, while the other half will receive a placebo (inactive substance) plus the same chemotherapy. Both groups will also have surgery and additional chemotherapy after the initial treatment.
Currently, standard chemotherapy alone helps some patients with advanced stomach cancer, but many still experience cancer recurrence or progression. Researchers believe that this medication might help by activating the body's immune system to better recognize and destroy cancer cells, potentially improving survival rates.
You likely qualify if…
You likely don't qualify if…
You will receive either the new medication or a placebo combined with chemotherapy intravenously over 3 to 4 cycles (about 2–3 months). After completing this initial treatment, you will have surgery to remove the cancer. Following surgery, you will receive 4 additional cycles of chemotherapy over about 3 months. Throughout this process, you will have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China